We use cookies to improve your experience on this website.

Exosome Therapeutics

For decades, researchers have recognized the enormous potential of exosomes but it is only in recent years that companies are seeing some success in developing technologies to engineer exosomes with predictable and reproducible properties to be loaded with therapeutic molecules and directed at specific target cells. The industry is working to develop a commercially scalable, efficient, and reproducible manufacturing process for this new class of biotherapeutics, and DPS has been privileged to design facilities to support clients at the forefront of these new processes.


 

    Project Profiles

  • Codiak, Clinical Manufacturing Facility

    The goals of this project were to assess current process manufacturing design and capabilities and identify future space and organizational needs.

    Location: Massachusetts
    Sector: Exosome Therapeutics
Back to top
DPS Group addresses the COVID-19 pandemic:
A message from Frank Keogh, CEO

Find out more Contact Us